Mechanisms of disease: Signal transduction in lung carcinogenesis-a comparison of smokers and never-smokers

Nature Clinical Practice Oncology

Volumn 5, Issue 10, 2008, Pages 610-618

  Mountzios, Giannis ^a   Fouret, Pierre ^b   Soria, Jean Charles ^b  

^a University Hospital Alexandra   (Greece)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; G PROTEIN COUPLED RECEPTOR; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR SUBSTRATE 1; INTEGRIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 12; MYC PROTEIN; NICOTINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN C JUN; PROTEIN KINASE B; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA;

CELL DIFFERENTIATION; CELL PROLIFERATION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG CARCINOMA; MALIGNANT TRANSFORMATION; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SMOKING; TOBACCO DEPENDENCE;

CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LUNG; LUNG NEOPLASMS; SIGNAL TRANSDUCTION; SMOKING;

EID: 53749104601     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1181     Document Type: Review

References (80)

1. Thun MJ and Jemal A (2006) How much of the decrease in cancer death rates in the United States is attributable to reductions in tobacco smoking? Tob Control 15: 345-347
2. Subramanian J and Govindan R (2007) Lung cancer in never smokers: A review. J Clin Oncol 25: 561-570
3. Jemal A et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66
4. [No authors listed] (2002) From the Centers for Disease Control and Prevention. State-specific prevalence of current cigarette smoking among adults, and policies and attitudes about secondhand smoke - United States, 2000. JAMA 287: 309-310
5. Dennis PA et al. (2005) The biology of tobacco and nicotine: Bench to bedside. Cancer Epidemiol Biomarkers Prev 14: 764-767
6. Hecht SS (2003) Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 3: 733-744
7. Akopyan G and Bonavida B (2006) Understanding tobacco smoke carcinogen NNK and lung tumorigenesis. Int J Oncol 29: 745-752
8. Tsurutani J et al. (2005) Tobacco components stimulate Akt-dependent proliferation and NFκB-dependent survival in lung cancer cells. Carcinogenesis 26: 1182-1195
9. Yang Y et al. (2004) Increased susceptibility of mice lacking Clara cell 10-kDa protein to lung tumorigenesis by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a potent carcinogen in cigarette smoke. J Biol Chem 279: 29336-29340
10. Schuller HM and Cekanova M (2005) NNK-induced hamster lung adenocarcinomas over-express β2-adrenergic and EGFR signaling pathways. Lung Cancer 49: 35-45
11. Schuller HM et al. (2000) Interaction of tobacco-specific toxicants with the neuronal alpha(7) nicotinic acetylcholine receptor and its associated mitogenic signal transduction pathway: Potential role in lung carcinogenesis and pediatric lung disorders. Eur J Pharmacol 393: 265-277
12. Jin Z et al. (2004) Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation. J Biol Chem 279: 40209-40219
13. Xu L and Deng X (2004) Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induces phosphorylation of mu- and m-calpain in association with increased secretion, cell migration, and invasion. J Biol Chem 279: 53683-53690
14. Stringer KA et al. (2004) Particulate phase cigarette smoke increases MnSOD, NQO1, and CINC-1 in rat lungs. Free Radic Biol Med 37: 1527-1533
15. Shopland DR et al. (1996) Cigarette smoking among U.S. adults by state and region: Estimates from the current population survey. J Natl Cancer Inst 88: 1748-1758
16. Toh CK et al. (2006) Never-smokers with lung cancer: Epidemiologic evidence of a distinct disease entity. J Clin Oncol 24: 2245-2251
17. Keohavong P et al. (1996) Detection of K-ras mutations in lung carcinomas: Relationship to prognosis. Clin Cancer Res 2: 411-418
18. Siegfried JM (2001) Women and lung cancer: Does oestrogen play a role? Lancet Oncol 2: 506-513
19. Ferguson MK et al. (1990) Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol 8: 1402-1407
20. Zeka A et al. (2006) Lung cancer and occupation in nonsmokers: A multicenter case-control study in Europe. Epidemiology 17: 615-623
21. Donington JS et al. (2006) Lung cancer in women: Exploring sex differences in susceptibility, biology, and therapeutic response. Clin Lung Cancer 8: 22-29
22. Stabile LP and Siegfried JM (2004) Estrogen receptor pathways in lung cancer. Curr Oncol Rep 6: 259-267
23. Gills JJ et al. (2004) Targeting aberrant signal transduction pathways in lung cancer. Cancer Biol Ther 3: 147-155
24. Bain C et al. (2004) Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst 96: 826-834
25. Franklin WA et al. (2002) Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 29 (Suppl 4): S3-S14
26. Shigematsu H et al. (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346
27. Lynch TJ et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139
28. Paez JG et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500
29. Shepherd FA et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132
30. Tsao MS et al. (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353: 133-144
31. Thatcher N et al. (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527-1537
32. Hirsch FR et al. (2006) Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24: 5034-5042
33. Engelman JA et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043
34. Pham D et al. (2006) Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 24: 1700-1704
35. Tang X et al. (2005) EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res 65: 7568-7572
36. Shigematsu H et al. (2005) Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65: 1642-1646
37. Stephens P et al. (2004) Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 431: 525-526
38. Papadimitrakopoulou V and Adjei AA (2006) The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy. J Thorac Oncol 1: 749-751
39. Adjei AA and Hidalgo M (2005) Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol 23: 5386-5403
40. Sato M et al. (2007) A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2: 327-343
41. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11-22
42. Eberhard DA et al. (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23: 5900-5909
43. Ahrendt SA et al. (2001) Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92: 1525-1530
44. Brose MS et al. (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62: 6997-7000
45. Erman M et al. (2005) Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features. Lung Cancer 47: 315-323
46. Vicent S et al. (2004) ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer 90: 1047-1052
47. Heusch WL and Maneckjee R (1998) Signalling pathways involved in nicotine regulation of apoptosis of human lung cancer cells. Carcinogenesis 19: 551-556
48. Kuo WH et al. (2005) Induction of apoptosis in the lung tissue from rats exposed to cigarette smoke involves p38/JNK MAPK pathway. Chem Biol Interact 155: 31-42
49. Mazieres J et al. (2005) Wnt signaling in lung cancer. Cancer Lett 222: 1-10
50. Vicent S et al. (2004) Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clin Cancer Res 10: 3639-3649
51. Greenberg AK et al. (2002) Selective p38 activation in human non-small cell lung cancer. Am J Respir Cell Mol Biol 26: 558-564
52. Tsai JR et al. (2006) Mitogen-activated protein kinase pathway was significantly activated in human bronchial epithelial cells by nicotine. DNA Cell Biol 25: 312-322
53. Olson JM and Hallahan AR (2004) P38 MAP kinase: A convergence point in cancer therapy Trends Mol Med 10: 125-129
54. Shin I et al. (2005) H-Ras-specific activation of Rac-MKK3/6-p38 pathway: Its critical role in invasion and migration of breast epithelial cells. J Biol Chem 280: 14675-14683
55. Bradham C and McClay DR (2006) p38 MAPK in development and cancer. Cell Cycle 5: 824-828
56. Turkson J et al. (1999) Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol Cell Biol 19: 7519-7528
57. Mountzios G et al.: Mitogen-activated protein kinase activation in lung adenocarcinoma: A comparative study between ever smokers and never smokers. Clin Cancer Res, in press)
58. Schmelzle T and Hall MN (2000) TOR, a central controller of cell growth. Cell 103: 253-262
59. Baselga J and Arribas J (2004) Treating cancer's kinase 'addiction'. Nat Med 10: 786-787
60. Brognard J et al. (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986-3997
61. Moore SM et al. (1998) The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res 58: 5239-5247
62. Mukohara T et al. (2003) Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer 41: 123-130
63. Blackhall FH et al. (2003) Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res 9: 2241-2247
64. David O et al. (2004) Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 10: 6865-6871
65. Cappuzzo F et al. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97: 643-655
66. Shah A et al. (2005) Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer. Clin Cancer Res 11: 2930-2936
67. Tang JM et al. (2006) Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51: 181 -191
68. Tsurutani J et al. (2005) Tobacco components stimulate Akt-dependent proliferation and NFκB-dependent survival in lung cancer cells. Carcinogenesis 26: 1182-1195
69. West KA et al. (2003) Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 111: 81-90
70. Lim WT et al. (2007) PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep 17 853-857
71. Dutu T et al. (2005) Differential expression of biomarkers in lung adenocarcinoma: A comparative study between smokers and never-smokers. Ann Oncol 16: 1906-1914
72. Yu H and Jove R (2004) The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 4: 97-105
73. Buettner R et al. (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945-954
74. Alvarez JV et al. (2006) Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 66: 3162-3168
75. Akca H et al. (2006) Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells. Lung Cancer 54: 25-33
76. Haura EB et al. (2005) Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 11: 8288-8294
77. Wright JG and Christman JW (2003) The role of nuclear factor kappa B in the pathogenesis of pulmonary diseases: Implications for therapy. Am J Respir Med 2: 211-219
78. Lemjabbar H et al. (2003) Tobacco smoke-induced lung cell proliferation mediated by tumor necrosis factor alpha-converting enzyme and amphiregulin. J Biol Chem 278: 26202-26207
79. Yang P et al. (2004) Glutathione pathway genes and lung cancer risk in young and old populations. Carcinogenesis 25: 1935-1944
80. Han CH et al. (2006) Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer. Oncol Rep 16: 1205-1210